TC Biopharm () (TCBP)
TC Biopharm () Statistics
Share Statistics
TC Biopharm () has 618.14K shares outstanding. The number of shares has increased by -79.62% in one year.
| Shares Outstanding | 618.14K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 49.59% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.93M |
| Failed to Deliver (FTD) Shares | 286.02K |
| FTD / Avg. Volume | 16.7% |
Short Selling Information
The latest short interest is 38.33K, so 7.75% of the outstanding shares have been sold short.
| Short Interest | 38.33K |
| Short % of Shares Out | 7.75% |
| Short % of Float | 0.65% |
| Short Ratio (days to cover) | 0.02 |
Valuation Ratios
The PE ratio is -417.14 and the forward PE ratio is -0.23.
| PE Ratio | -417.14 |
| Forward PE | -0.23 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 917.62 |
| P/FCF Ratio | -231.25 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TC Biopharm ().
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.2, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.2 |
| Quick Ratio | 1.2 |
| Debt / Equity | 0.67 |
| Total Debt / Capitalization | 40.15 |
| Cash Flow / Debt | -5.85 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.2% and return on capital (ROIC) is -267.99%.
| Return on Equity (ROE) | -2.2% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | -267.99% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -144.07K |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.09M |
| Effective Tax Rate | 0.16 |
Stock Price Statistics
The stock price has increased by -96.65% in the last 52 weeks. The beta is 0.25, so TC Biopharm ()'s price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | -96.65% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 4.85 |
| Relative Strength Index (RSI) | 29.01 |
| Average Volume (20 Days) | 1.71M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -14.24M |
| Net Income | -5.91M |
| EBITDA | -13.61M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 2.46M in cash and 1.80M in debt, giving a net cash position of 661.45K.
| Cash & Cash Equivalents | 2.46M |
| Total Debt | 1.80M |
| Net Cash | 661.45K |
| Retained Earnings | -38.84M |
| Total Assets | 6.87M |
| Working Capital | 423.86K |
Cash Flow
In the last 12 months, operating cash flow was -10.54M and capital expenditures -110.35K, giving a free cash flow of -10.66M.
| Operating Cash Flow | -10.54M |
| Capital Expenditures | -110.35K |
| Free Cash Flow | -10.66M |
| FCF Per Share | -0.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -15.15% |
| FCF Yield | -26.44% |
Analyst Forecast
The average price target for TCBP is $2.4, which is 627.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.4 |
| Price Target Difference | 627.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jan 7, 2025. It was a forward split with a ratio of 5:4.
| Last Split Date | Jan 7, 2025 |
| Split Type | forward |
| Split Ratio | 5:4 |
Scores
| Altman Z-Score | -9.77 |
| Piotroski F-Score | 2 |